ARTERIAL HYPERTENSION IN POST-ACUTE SEQUELAE OF SARS-COV-2 INFECTION AND RENIN-ANGIOTENSIN-SYSTEM GENE POLYMORPHISMS

Highlights

Uncontrolled hypertension is not a rare manifestation of post-COVID syndrome. Given the fact that RAAS is interested in the penetration of the virus into the body, it can be assumed that uncontrolled hypertension after COVID-19 is associated with polymorphism of genes encoding angiotensin II. The presented review is the result of a thorough search of relevant articles in the databases of scientific electronic libraries eLIBRARY.RU, PubMed, Cyberleninka as of November 5, 2024.

Absract

The term “long COVID” (PASC) has gained international recognition and is widely used to describe a wide range of symptoms after COVID-19. According to international studies, at least 65 million people worldwide suffer from PASC, and the number of cases is increasing. A new paradigm of PASC is proposed, which includes biological, psychological and social factors integrated into a single model. Genetic polymorphisms are a key element of the biological component of the paradigm. Taking into account the pathogenesis of COVID-19, the role of genetic polymorphisms of the components of the renin-angiotensin-aldosterone system (RAAS) in the development of PASC is discussed. However, the results of international studies are not unambiguous. The documented high risk of developing PASC in patients with arterial hypertension, the occurrence of uncontrolled arterial hypertension after infection, makes it possible to isolate the corresponding subphenotype in the cardiovascular phenotypic profile of PASC. The genetic architecture of blood pressure includes genetic polymorphisms of the RAAS components. Given the involvement of RAAS, it seems promising to study candidate gene polymorphisms in uncontrolled arterial hypertension within the framework of PASC. Studying this part of the molecular mechanisms of PASC pathogenesis opens up opportunities for personalized treatment strategies.

1. Ballering A.V., van Zon S.K.R., Olde Hartman T.C., Rosmalen J.G.M. Lifelines Corona Research Initiative. Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study. Lancet. 2022; 400 (10350): 452-461. doi:10.1016/S0140-6736(22)01214-4.

2. O'Mahoney L.L., Routen A., Gillies C. et al. Corrigendum to "The prevalence and long-term health effects of long Covid among hospitalised and non-hospitalised populations: a systematic review and meta-analysis". EClinicalMedicine. 2023; 59: 101959. doi:10.1016/j.eclinm.2023.101959.

3. World Health Organization A Clinical Case Definition of Post COVID-19 Condition by a Delphi Consensus. Available at: https://www.who.int/publications/i/item/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1 (accessed 05.12.2024).

4. Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023; 21 (3): 133-146. doi:10.1038/s41579-022-00846-2.

5. Xie Y., Xu E., Bowe B., Al-Aly Z. Long-term cardiovascular outcomes of COVID-19. Nat. Med. 2022; 28: 583–590. doi:10.1038/s41591-022-01689-3.

6. Constantinescu-Bercu A., Lobiuc A., Căliman-Sturdza O.A. et al. Long COVID: Molecular Mechanisms and Detection Techniques. Int J Mol Sci. 28; 25(1): 408. doi:10.3390/ijms25010408.

7. Saunders C., Sperling S., Bendstrup E. A new paradigm is needed to explain long COVID. Lancet Respir Med. 2023; 11(2): 12-13. doi:10.1016/S2213-2600(22)00501-X.

8. Udomsinprasert W., Nontawong N., Saengsiwaritt W. et al. Host genetic polymorphisms involved in long-term symptoms of COVID-19. Emerg Microbes Infect. 2023; 12(2): 2239952. doi:10.1080/22221751.2023.2239952.

9. Ni W., Yang X., Yang D. et al. Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19. Crit. Care. 2020; 24: 422. doi:10.1186/s13054-020-03120-0.

10. Glotov O.S., Chernov A.N., Scherbak S.G., Baranov V.S. Genetic risk factors for the development of COVID-19 coronavirus infection. Russ. J. Genet. 2021; 57: 878-892. doi: 10.1134/S1022795421080056 (In Russian)

11. Sheikhian. F., Sadeghi M.S., Tarashi, S. et al. The impact of ACE2 polymorphisms (rs1978124, rs2285666, and rs2074192) and ACE1 rs1799752 in the mortality rate of COVID-19 in different SARS-CoV-2 variants. Hum Genomics. 2023; 17(1): 54. doi: 10.1186/s40246-023-00501-8.

12. Novelli A., Biancolella M., Borgiani P. et al. Analysis of ACE2 genetic variants in 131 Italian SARS-CoV-2-positive patients. Hum Genomics. 2020 Sep 11; 14(1): 29. doi: 10.1186/s40246-020-00279-z.

13. Cafiero C., Rosapepe F., Palmirotta R. et al. Angiotensin System Polymorphisms' in SARS-CoV-2 Positive Patients: Assessment Between Symptomatic and Asymptomatic Patients: A Pilot Study. Pharmgenomics Pers Med. 2021; 14: 621-629. doi: 10.2147/PGPM.S303666.

14. Ibañez C., Perdomo J., Calvo A. et al. High D dimers and low global fibrinolysis coexist in COVID19 patients: what is going on in there? J Thromb Thrombolysis. 2021; 51(2): 308-312. doi: 10.1007/s11239-020-02226-0.

15. Gorog D.A., Storey R.F., Gurbel P.A. et al. (2022) Current and novel biomarkers of thrombotic risk in COVID-19: a Consensus Statement from the International COVID-19 Thrombosis Biomarkers Colloquium. Nat Rev Cardiol 2022; 19(7): 475-495. doi: 10.1038/s41569-021-00665-7

16. Fiorentino G., Benincasa G., Coppola A. et al. Targeted genetic analysis unveils novel associations between ACE I/D and APO T158C polymorphisms with D-dimer levels in severe COVID-19 patients with pulmonary embolism. J Thromb Thrombolysis. 2023; 55(1): 51-59. doi: 10.1007/s11239-022-02728-z.

17. Saab Y.B., Nakad Z.S., Mehanna S.J. Association of the ACE and AGT gene polymorphisms with global disparities in COVID-19-related deaths. Pharmacogenet Genomics. 2023 1; 33(3) :41-50. doi: 10.1097/FPC.0000000000000492.

18. Bragina A.E., Tarzimanova A.I., Rodionova Y.N. et al. Renin-Angiotensin System Genes Polymorphisms in Patients With COVID-19 and Its Relation to Severe Cases of SARS-CoV-2 Infection. J Clin Med Res. 2024; 16(7-8): 355-362. doi: 10.14740/jocmr5223.

19. Patel S.K., Juno J.A., Lee W.S. et al. Plasma ACE2 activity is persistently elevated following SARS-CoV-2 infection: implications for COVID-19 pathogenesis and consequences. Eur Respir J. 2021; 57(5): 2003730. doi: 10.1183/13993003.03730-2020.

20. Castanares-Zapatero D., Chalon P., Kohn L. et al. Pathophysiology and mechanism of long COVID: a comprehensive review. Ann Med. 2022; 54(1): 1473-1487. doi: 10.1080/07853890.2022.2076901.

21. The PHOSP-COVID Collaborative Group Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: A prospective observational study. Lancet Respir. Med. 2022;10:761–775. doi: 10.1016/S2213-2600(22)00127-8.

22. Fernández-de-Las-Peñas C., Arendt-Nielsen L., Díaz-Gil G. et al. Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors. Genes (Basel). 2022; 13(11): 1935. doi: 10.3390/genes13111935.

23. Fernández-de-Las-Peñas C., Arendt-Nielsen L., Díaz-Gil G. et al. ACE1 rs1799752 polymorphism is not associated with long-COVID symptomatology in previously hospitalized COVID-19 survivors. J Infect. 2023; 86(3): 67-69. doi: 10.1016/j.jinf.2022.12.026.

24. Lammi V., Nakanishi T., Jones S.E. et al. Genome-wide Association Study of Long COVID. medRxiv. 2023. preprint. doi: https://doi.org/10.1101/2023.06.29.23292056

25. Luo Y.S., Zhang K., Cheng Z.S.. Absence of Association between a Long COVID and Severe COVID-19 Risk Variant of FOXP4 and Lung Cancer. Front Genet. 2023; 14: 1258829. doi: 10.3389/fgene.2023.1258829.

26. Schmidt-Lauber C., Alba Schmidt E., Hänzelmann S. et al. Increased blood pressure after nonsevere COVID-19. J Hypertens. 2023 ; 41(11) :1721-1729. doi: 10.1097/HJH.0000000000003522.

27. Angeli F., Zappa M., Verdecchia P. Global burden of new-onset hypertension associated with severe acute respiratory syndrome coronavirus 2 infection. Eur J Intern Med. 2024; 119: 31-33. doi: 10.1016/j.ejim.2023.10.016.

28. Bielecka E., Sielatycki P., Pietraszko P. et al. Elevated Arterial Blood Pressure as a Delayed Complication Following COVID-19-A Narrative Review. Int J Mol Sci. 2024; 25(3): 1837. doi: 10.3390/ijms25031837.

29. Chazova I.E., Blinova N.V., Zhernakova J.V. et al. Russian medical society expert consensus on arterial hypertension: arterial hypertension and Post-COVID syndrome. Systemic Hypertension. 2022; 19(3): 5-13. doi:10.38109/2075-082X-2022-3-5-13 (In Russian)

30. Hengel F.E., Benitah J.P., Wenzel U.O. Mosaic theory revised: inflammation and salt play central roles in arterial hypertension. Cell Mol Immunol. 2022; 19(5): 561-576. doi:10.1038/s41423-022-00851-8.

31. Magavern E.F., Warren H.R., Ng F.L. et al. An Academic Clinician's Road Map to Hypertension Genomics: Recent Advances and Future Directions MMXX. Hypertension. 2021; 77(2): 284-295. doi: 10.1161/HYPERTENSIONAHA.120.14535.

32. Lip S., Padmanabhan S. Genomics of Blood Pressure and Hypertension: Extending the Mosaic Theory Toward Stratification. Can J Cardiol. 2020; 36(5): 694-705. doi: 10.1016/j.cjca.2020.03.001.

33. Elkina A. Yu., Akimova N. S., Shvarts Yu. G. Polymorphism of ACE, AGT, AGTR1 genes as genetic predictors of hypertension. Russian Journal of Cardiology. 2021;26(S1):4143. doi:10.15829/1560-4071-2021-4143 (In Russian)

34. Evangelou E., Warren H.R., Mosen-Ansorena D. et al. Genetic analysis of over 1 million people identifies 535 new loci associated with blood pressure traits. Nat Genet. 2021; 77(2): 284-295. doi: 10.1038/s41588-018-0205-x

35. Zhang H.G., Dagliati A., Shakeri Hossein Abad Z. et al. International electronic health record-derived post-acute sequelae profiles of COVID-19 patients. NPJ Digit Med. 2022; 5(1): 81. doi: 10.1038/s41746-022-00623-8.

36. Dagliati A., Strasser Z.H., Hossein Abad Z.S. et al. Characterization of long COVID temporal sub-phenotypes by distributed representation learning from electronic health record data: a cohort study. EClinicalMedicine. 2023; 64: 102210. doi: 10.1016/j.eclinm.2023.102210.

37. Arutyunov A. G., Seferovic P., Bakulin I. G. et al. Rehabilitation after COVID-19. Resolution of the International Expert Council of the Eurasian Association of Therapists and the Russian Society of Cardiology. Russian Journal of Cardiology. 2021;26(9):4694. (In Russian)

38. Vaduganathan M., Vardeny O., Michel T. et al. Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Covid-19. N Engl J Med. 2020; 382(17): 1653-1659. doi:10.1056/NEJMsr2006760.

39. König S., Vollenberg R., Tepasse P.R. The Renin-Angiotensin System in COVID-19: Can Long COVID Be Predicted? Life (Basel). 2023; 13(7): 1462. doi: 10.3390/life13071462.

40. Tepasse P.R., Vollenberg R., Steinebrey N. et al. The Dysregulation of the Renin-Angiotensin System in COVID-19 Studied by Serum Proteomics: Angiotensinogen Increases with Disease Severity. Molecules. 2022; 27(8): 2495. doi: 10.3390/molecules27082495.

41.